Assessment of transdermal fentanyl combined with gabapentin for malignant neuropathic pain treatment

Chinese Journal of Clinical Oncology

Volumn 41, Issue 20, 2014, Pages 1307-1311

  Ding, Yuanyuan ^a   Yao, Peng ^a   Lan, Peili ^a   Ma, Jiaming ^a   Wang, Zhibin ^a   Hong, Tao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Gabapentin; Malignant neuropathic pain; Transdermal fentanyl

Indexed keywords

FENTANYL; GABAPENTIN; MORPHINE;

ANALGESIA; ARTICLE; BREAKTHROUGH PAIN; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEUROPATHIC PAIN; NEUROPATHIC PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 84914675510     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.20141212     Document Type: Article

References (15)

1. Jensen TS, Baron R, Haanp SM M, et al. A new definition of neuropathic pain[J] Pain, 2011, 152(10):2204-2205.
2. Li ZL, An JX, Ni JX, et al. Clinical pain therapy[M]. 3rd editon. Tianjin: Tianin Science and Technology Press, 2003:255-380.
3. Argoff CE, Katz N, Backonja M, Treatment of postherpetic neuralgia: a review of therapeutic options[J]. J Pain Symptom Manage, 2004, 28(4):396-411.
4. Huang X, Zhang WJ, Cai CS. Clinical assessment of oxycontin in moderate or severe cancer pain therapy[J] Strait Pharmaceutical Journal, 2010, 29(1):6
5. Bilen A, Ali A, Alkan I, et al. Comparison of transdermal fentanyl for the management of cancer pain in adults and elders[J] Agri, 2012, 24(3):111-116.
6. Guo SP, Wu SG, Zhou J, et al. Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life[J] Drug Des Devel Ther, 2014, 12(8):497-503.
7. Cachia E, Ahmedzai SH. Transdermal opioids for cancer pain[J]. Curr Opin Support Palliat Care, 2011, 5(1):15-19.
8. Hata A, Katakami N, Masuda Y, et al. Direct low-dose fentanyl patch (2.1mg) introduction for opioid naive outpatients with cancer pain[J]. Gan To Kagaku Ryoho, 2011, 38(3):415-118.
9. Meng FY, Zhang LC, Liu Y, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials[J] Minerva Anestesiol, 2014, 80(5):556-567.
10. Khadem T, Stevens V. Therapeutic options for the treatment of postherpetic neuralgia: a systematic review[J] J Pain Palliat Care Pharmacother, 2013, 27(3):268-283.
11. Yoshizumi M, Parker RA, Eisenach JC, et al. Gabapendn inhibits y-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats[J]. Anesthesiology, 2012, 116(6):1347-1353.
12. Parker DA, Ong J, Marino V, et al. Gabapendn activates presynaptic GABAB heteroreceptors in rat cortical slices[J]. Eur J Pharmacol, 2004, 495(2-3):137-143.
13. Stefani A, Spadoni F, Giacomini P, et al. The effects of gabapentin on different ligand- and voltage-gated currents in isolated cortical neurons[J] Epilepsy Res, 2001, 43(3):239-248.
14. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain[J] Arch Pharm Res, 2013, 36(3):237-251.
15. Yeh CY, Chung SC, Tseng EL, et al. Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats[J] Acta Anaesthesiol Taiwan, 2011, 49(4):144-148.